Curis (CRIS) AI Stock Analysis

1,457 Followers

Top Page

Curis

(NASDAQ:CRIS)

49Neutral

Curis is facing serious financial challenges, with persistent losses and a fragile balance sheet posing significant risks. However, promising results in clinical trials provide potential upside, especially if the company can secure additional funding to extend its cash runway. Technical indicators reflect short-term positive momentum, but valuation concerns remain due to the lack of profits. Overall, while the company's clinical pipeline shows promise, financial instability and valuation risks temper the stock's attractiveness.

Positive Factors

Clinical Trial Results

Investigators have expressed enthusiasm about the PCNSL data to date, citing its consistency, the clarity of the mechanism of action, strong preclinical support, and observed patient responses aligning with expectations.

Regulatory Approval

Feedback from the FDA and EU CHMP supports a potential path for accelerated approval of emavusertib + ibrutinib, based on the Phase 1/2 single arm trial in r/r PCNSL.

Negative Factors

Enrollment Challenges

The primary challenge is the difficulty of enrollment, given the small patient population.

Stock Valuation

The price target is being lowered due to dilution from a recent raise, which could impact the stock's valuation.

Curis (CRIS) vs. S&P 500 (SPY)

Market Cap

$22.18M

Dividend YieldN/A

Average Volume (3M)115.78K

Price to Earnings (P/E)―

Beta (1Y)2.92

Revenue Growth14.17%

EPS Growth28.26%

CountryUS

Employees34

SectorHealthcare

Sector Strength39

IndustryBiotechnology

Share Statistics

EPS (TTM)1.25

Shares Outstanding10,462,250

10 Day Avg. Volume126,177

30 Day Avg. Volume115,779

Financial Highlights & Ratios

PEG Ratio-0.05

Price to Book (P/B)-2.42

Price to Sales (P/S)0.00

P/FCF Ratio-0.50

Enterprise Value/Market Cap0.12

Enterprise Value/Revenue0.07

Enterprise Value/Gross Profit0.26

Enterprise Value/Ebitda-0.01

Forecast

1Y Price Target

$14.00

Price Target Upside600.00% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Curis Business Overview & Revenue Model

Company DescriptionCuris, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

How the Company Makes MoneyCuris primarily makes money through the development and commercialization of its proprietary drug candidates, focusing on oncology therapies. The company generates revenue from strategic collaborations and licensing agreements with pharmaceutical and biotechnology firms, which may include upfront payments, milestone payments, and royalties on product sales. Additionally, Curis may receive research and development funding from partners to support its clinical trials and drug development efforts. The company's revenue model heavily relies on successful clinical trial outcomes and obtaining regulatory approval for its drug candidates.

Curis Financial Statement Overview

Summary

Curis faces significant financial challenges with persistent losses and negative cash flows. Although there has been some revenue growth, the company's profitability and balance sheet stability are concerning. The financial health of Curis is fragile, with potential risks stemming from negative equity and ongoing operational losses.

Income Statement

Neutral

Curis shows a slight increase in revenue from the previous year, but the company still suffers from significant negative net income and EBIT margins, indicating ongoing profitability issues. The gross profit margin remains positive, but the net profit margin is deeply negative, reflecting operational challenges.

Balance Sheet

Negative

The balance sheet reveals a negative stockholders' equity, which is concerning, indicating that liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity. This highlights potential solvency issues and financial instability.

Cash Flow

Negative

Curis has negative free cash flow and operating cash flow, which are troubling. The cash flow from operations is consistently negative, which may indicate difficulties in generating cash from core activities. Despite some improvement in cash flow from investing activities, the overall cash flow position remains weak.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
10.91M	10.02M	10.16M	10.65M	10.84M
	Gross Profit
10.81M	9.81M	9.90M	10.12M	10.30M
	EBIT
-44.54M	-48.33M	-53.02M	-42.06M	-24.90M
	EBITDA
-42.57M	-45.14M	-50.51M	-39.98M	-24.67M
	Net Income Common Stockholders
-43.39M	-47.41M	-60.32M	-50.64M	-34.88M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
20.00M	56.33M	85.62M	139.85M	183.06M
	Total Assets
41.27M	77.28M	108.85M	162.30M	204.36M
	Total Debt
2.95M	2.79M	6.74M	5.04M	7.66M
	Net Debt
-17.04M	-23.89M	-12.92M	-34.97M	-121.95M
	Total Liabilities
47.26M	57.61M	62.30M	71.59M	73.69M
	Stockholders Equity
-6.00M	19.67M	46.55M	90.71M	130.67M
Cash Flow		Free Cash Flow
-39.56M	-38.43M	-54.75M	-37.62M	-26.42M
	Operating Cash Flow
-39.56M	-38.43M	-54.34M	-37.62M	-25.74M
	Investing Cash Flow
29.44M	37.79M	33.02M	-47.90M	-49.05M
	Financing Cash Flow
3.44M	7.58M	867.00K	-4.17M	188.81M

Curis Technical Analysis

Technical Analysis Sentiment

Negative

Last Price2.00

Price Trends

50DMA

2.05

Negative

100DMA

2.66

Negative

200DMA

3.74

Negative

Market Momentum

MACD

0.06

Negative

RSI

51.33

Neutral

STOCH

23.26

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRIS, the sentiment is Negative. The current price of 2 is above the 20-day moving average (MA) of 1.87, below the 50-day MA of 2.05, and below the 200-day MA of 3.74, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 51.33 is Neutral, neither overbought nor oversold. The STOCH value of 23.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRIS.

Curis Risk Analysis

Curis disclosed 61 risk factors in its most recent earnings report. Curis reported the most risks in the “Finance & Corporate” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Curis Peers Comparison

Overall Rating

UnderperformOutperform

Sector (52)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VVOS	57 Neutral	$18.49M	―	-266.25%	―	8.91%	70.18%
Sector *	52 Neutral	$5.14B	3.39	-43.55%	2.83%	16.49%	-0.19%
CRIS	49 Neutral	$22.18M	―	-2951.24%	―	14.17%	28.26%
LSTA	43 Neutral	$19.60M	―	-56.49%	―	―	7.07%
BCAB	35 Underperform	$25.68M	―	-246.21%	―	―	44.38%
UBX	31 Underperform	$13.94M	―	-231.27%	―	―	35.08%
CVM	27 Underperform	$21.78M	―	-227.76%	―	―	30.96%

* Healthcare Sector Average

Performance Comparison

CRIS

Curis

2.00

-11.00

-84.62%

CVM

Cel-Sci

0.24

-1.20

-83.33%

LSTA

Lisata Therapeutics

2.18

-0.66

-23.24%

UBX

Unity Biotechnology

0.74

-0.79

-51.63%

VVOS

Vivos Therapeutics

3.04

0.86

39.45%

BCAB

BioAtla

0.41

-2.59

-86.33%

Curis Earnings Call Summary

Earnings Call Date:May 06, 2025

(Q1-2025)

% Change Since: -18.37%|

Next Earnings Date:Jul 31, 2025

Earnings Call Sentiment Positive

The earnings call highlighted significant progress in clinical trials, especially with emavusertib in PCNSL and AML, showing strong potential for future growth. Financial performance improved, though there is a concern about the limited cash runway. Overall, the positive developments in clinical trials outweigh the financial concerns.

Q1-2025 Updates

Positive Updates

Strong Progress in PCNSL Study

The TakeAim lymphoma study evaluating emavusertib in combination with ibrutinib showed promising results with 9 out of 13 BTKI-experienced patients showing tumor reduction. The study is on track to support accelerated submissions in both the U.S. and Europe.

Significant Improvement Over Existing Treatments in AML

Emavusertib showed a 38% composite CR rate in a study with relapsed/refractory AML patients, which is a significant improvement over gilteritinib's 21% CR rate, highlighting emavusertib's novel mechanism of action.

Successful Financial Management

Curis reported a decreased net loss of $10.6 million compared to $11.9 million last year and completed a registered direct financing with net proceeds of $8.8 million.

Negative Updates

Limited Cash Runway

Curis' cash and cash equivalents are expected to fund operations only until the fourth quarter of 2025, indicating a potential need for additional funding in the near term.

Company Guidance

During Curis' first quarter 2025 business update call, the company provided several key metrics and updates on their ongoing efforts. In their TakeAim lymphoma study, which evaluates emavusertib in combination with ibrutinib for primary CNS lymphoma (PCNSL), 27 patients with relapsed/refractory PCNSL have been treated, including 7 BTKI-naive patients and 20 BTKI-experienced patients. Among the BTKI-experienced group, 6 out of 13 response-evaluable patients demonstrated a reduction in tumor burden, with 4 achieving complete responses, 3 of which lasted over 6 months. In the BTKI-naive group, all 5 evaluable patients showed objective responses. Additionally, Curis reported a net loss of $10.6 million for the first quarter, with cash and cash equivalents totaling $20.3 million as of March 31, 2025, expected to fund operations into the fourth quarter of 2025. The company continues to focus on enrolling 30 to 40 additional patients for their NDA submission and is planning further data releases at the upcoming ASH conference.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.